RecruitingNCT07118137

Memory Deterioration in Alzheimer Disease

Translational Neuroscience CAG for Alzheimer's Disease


Sponsor

Norwegian University of Science and Technology

Enrollment

30 participants

Start Date

Oct 15, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Semantic AD


Eligibility

Min Age: 55 Years

Inclusion Criteria4

  • Confirmed diagnosis based on current ICD criteria for AD or MCI .
  • \>55years.
  • Norwegian native speaker
  • Lives at home and not in a health institution

Exclusion Criteria10

  • Patients with severe cognitive impairment that prevents assessment with the selected modalities (planned cut-off: CDR \> 2).
  • Presence of brain tumors.
  • History of traumatic brain injury.
  • History of cranial surgery.
  • Contraindications to the selected imaging modalities (e.g., 7T MRI or EEG).
  • Diagnosis of other neurodegenerative diseases such as Parkinson's disease or ALS.
  • T MRI contraindications:
  • Large tattoos close to the head region, permanent makeup or unremoveable piercings
  • Certain models of pacemakers (if pacemaker implantet, MRI physicist at 7T-lab will be conferred)
  • Implantet metal in body (clips, stents, prothesis, skrews, plates, teeth etc.)

Interventions

DEVICE7T MRI

Resting and activity-based MRI. Dring activity based MRI, the participant will complete tasks testing semantic memory.

DEVICEEEG

Resting-state EEG

BIOLOGICALBlood samples

Blood samples taken for analysis of central blood biomarkers.

BIOLOGICALStool samples

Stool samples collected to identify distinct gut-microbiota compositions between the groups.

DIAGNOSTIC_TESTNeuropsychologic test (MoCA)

Map cognition with clinically well-established neuropsychology test


Locations(1)

Norwegian University of Sciene and Technology / Norges teknisk-naturvitenskapelige universitet (NTNU)

Trondheim, Trønderlag, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07118137


Related Trials